• Merck's Welireg with lenvatinib received a positive EU CHMP opinion for advanced clear cell kidney cancer following PD-1/PD-L1 inhibitor treatment.
• A European Commission decision on marketing authorization is expected within two months.
• The combination reduced disease progression or death risk by 26% versus cabozantinib; overall survival improvement was not statistically significant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611130635BIZWIRE_USPR_____20261112_BW893799) on November 13, 2026, and is solely responsible for the information contained therein.